Literature DB >> 19967725

Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.

Jason Madore1, Fengge Ren, Ali Filali-Mouhim, Lilia Sanchez, Martin Köbel, Patricia N Tonin, David Huntsman, Diane M Provencher, Anne-Marie Mes-Masson.   

Abstract

The histopathological diagnosis of high-grade endometrioid and serous carcinoma of the ovary is poorly reproducible under the current morphology based classification system, especially for anaplastic, high-grade tumours. The transcription factor Wilms' tumour-1 (WT1) is differentially expressed among the gynaecological epithelia from which epithelial ovarian cancers (EOCs) are believed to originate. In EOCs, WT1 protein is observed in the majority of serous carcinomas and in up to 30% of endometrioid carcinomas. It is unclear whether the latter is a reflection of the actual incidence of WT1 protein expression in endometrioid carcinomas, or whether a significant number of high-grade serous carcinomas have been misclassified as endometrioid carcinoma. Several genetic aberrations are reported to occur in EOCs. These include mutation of the TP53 gene, aberrant activation of beta-catenin signalling and loss of PTEN protein expression, among others. It is unclear whether these aberrations are histotype-specific. The aim of this study was to better define the molecular characteristics of serous and endometrioid carcinomas in an attempt to address the problems with the current histopathological classification methods. Gene expression profiles were analysed to identify reproducible gene expression phenotypes for endometrioid and serous carcinomas. Tissue microarrays (TMA) were used to assess the incidence of TP53, beta-catenin and PTEN aberrations in order to correlate their occurrence with WT1 as an immunohistochemistry based biomarker of serous histotype. It was found that nuclear WT1 protein expression can identify misclassified high-grade endometrioid carcinomas and these tumours should be reassigned to serous histotype. Although low-grade endometrioid carcinomas rarely progress to high-grade carcinomas, a combined WT1-negative, TP53-positive immunophenotype may identify an uncommon high-grade subtype of ovarian endometrioid carcinoma. GEO database: array data accession number GSE6008. Copyright 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19967725     DOI: 10.1002/path.2659

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  36 in total

1.  Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups.

Authors:  Carlos Parra-Herran; Jordan Lerner-Ellis; Bin Xu; Sam Khalouei; Dina Bassiouny; Matthew Cesari; Nadia Ismiil; Sharon Nofech-Mozes
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Telomere length and genetic variation in telomere maintenance genes in relation to ovarian cancer risk.

Authors:  Kathryn L Terry; Shelley S Tworoger; Allison F Vitonis; Jason Wong; Linda Titus-Ernstoff; Immaculata De Vivo; Daniel W Cramer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-01-20       Impact factor: 4.254

3.  Rethinking ovarian cancer: recommendations for improving outcomes.

Authors:  Sebastian Vaughan; Jermaine I Coward; Robert C Bast; Andy Berchuck; Jonathan S Berek; James D Brenton; George Coukos; Christopher C Crum; Ronny Drapkin; Dariush Etemadmoghadam; Michael Friedlander; Hani Gabra; Stan B Kaye; Chris J Lord; Ernst Lengyel; Douglas A Levine; Iain A McNeish; Usha Menon; Gordon B Mills; Kenneth P Nephew; Amit M Oza; Anil K Sood; Euan A Stronach; Henning Walczak; David D Bowtell; Frances R Balkwill
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

4.  The loss of Hoxa5 function causes estrous acyclicity and ovarian epithelial inclusion cysts.

Authors:  Gaëlle Gendronneau; Olivier Boucherat; Josée Aubin; Margot Lemieux; Lucie Jeannotte
Journal:  Endocrinology       Date:  2012-02-07       Impact factor: 4.736

5.  Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.

Authors:  Martin Köbel; Steve E Kalloger; Sandra Lee; Máire A Duggan; Linda E Kelemen; Leah Prentice; Kimberly R Kalli; Brooke L Fridley; Daniel W Visscher; Gary L Keeney; Robert A Vierkant; Julie M Cunningham; Christine Chow; Roberta B Ness; Kirsten Moysich; Robert Edwards; Francesmary Modugno; Clareann Bunker; Eva L Wozniak; Elizabeth Benjamin; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; C Blake Gilks; David G Huntsman; Susan J Ramus; Ellen L Goode
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-07-23       Impact factor: 4.254

Review 6.  The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention".

Authors:  Christopher P Crum; Frank D McKeon; Wa Xian
Journal:  Clin Obstet Gynecol       Date:  2012-03       Impact factor: 2.190

Review 7.  Molecular targeted therapy in ovarian cancer: what is on the horizon?

Authors:  Roshni Kalachand; Bryan T Hennessy; Maurie Markman
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

8.  Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures.

Authors:  Boris Winterhoff; Habib Hamidi; Chen Wang; Kimberly R Kalli; Brooke L Fridley; Judy Dering; Hsiao-Wang Chen; William A Cliby; He-Jing Wang; Sean Dowdy; Bobbie S Gostout; Gary L Keeney; Ellen L Goode; Gottfried E Konecny
Journal:  Gynecol Oncol       Date:  2016-04       Impact factor: 5.482

9.  The role of the PTEN/PI3K/Akt pathway on prognosis in epithelial ovarian cancer: a meta-analysis.

Authors:  Jing Cai; Linjuan Xu; Huijuan Tang; Qiang Yang; Xiaoqing Yi; Yan Fang; Ying Zhu; Zehua Wang
Journal:  Oncologist       Date:  2014-04-09

10.  A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer.

Authors:  Jean-Philippe Meyniel; Paul H Cottu; Charles Decraene; Marc-Henri Stern; Jérôme Couturier; Ingrid Lebigot; André Nicolas; Nina Weber; Virginie Fourchotte; Séverine Alran; Audrey Rapinat; David Gentien; Sergio Roman-Roman; Laurent Mignot; Xavier Sastre-Garau
Journal:  BMC Cancer       Date:  2010-05-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.